U.S. authorities now allege that the two top officials of CANARX, a Windsor, Ontario company, ran a long-running scheme to illegally import prescription drugs into the United States. According to court records filed Tuesday, John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges. His brother Bob Howard, the president and a director, is wanted in the same federal investigation and has not yet been taken into custody. Neither has entered a plea. The charges are allegations, and they should be tested in court.

Still, the record behind these allegations is hard to ignore. An affidavit from FDA special agent Dustin Dobbs states there is probable cause to believe CANARX illegally imported or caused the illegal importation of prescription drugs. The criminal complaint covers the period from Feb. 22, 2017, through April 15, 2026. The affidavit does not say which medications were involved, and that gap matters for patients who want to know what they were given. The company has also drawn FDA scrutiny before: a 2019 warning letter, a 2023 seizure of medication described as potentially misbranded and counterfeit, and a pending civil suit from Gilead Sciences over the HIV drug Biktarvy.

The company's defense is that its medicines come from highly regulated countries and that it operates legally. That claim deserves a hearing in court, not a press release. But the central legal question is not complicated. An FDA spokesperson said last year that, in most circumstances, a person cannot import prescription drugs from other countries as substitutes for FDA-approved drugs. Alternative funding programs have built their models on a narrow individual-use exception, and CNBC's reporting found those programs spreading through private and public employers, some of which require staff to use them.

Regulators and lawmakers should not wait for each company to be prosecuted one at a time. They should close the gap between what these programs promise, cheaper specialty drugs, and what the law permits. Employers that mandate these programs should be asked to justify that choice to their workers. Patients deserve clear answers about where their medication was made, who handled it, and whether it was authorized by the manufacturer. Until those answers are routine, the savings pitch should be treated with suspicion.